Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Sex-linked Disorders01:43

Sex-linked Disorders

102.6K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
102.6K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

36
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
36
Cross-bridge Cycle01:26

Cross-bridge Cycle

117.9K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>COASY</i>-Associated Disorders as a Differential Diagnosis in Cases with Newborn Screening Results Suggestive of CPT-I.

International journal of neonatal screeningยท2026
Same author

Prenatal Diagnosis of Spinal Muscular Atrophy Facilitates Ultrarapid Treatment After Birth.

Pediatric neurologyยท2026
Same author

Longitudinally-extensive transverse myelitis in the setting of recent Mycoplasma infection: Case series.

Journal of neuroimmunologyยท2025
Same author

Outcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study.

Muscle & nerveยท2024
Same author

Pearls & Oy-sters: Use of Muscle Ultrasound as a Clinical Tool in INPP5K-Related Muscular Dystrophy: A Case Report.

Neurologyยท2024
Same author

Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening.

International journal of neonatal screeningยท2024
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)ยท2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)ยท2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)ยท2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)ยท2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)ยท2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)ยท2026
See all related articles

Related Experiment Video

Updated: Aug 16, 2025

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

8.5K

The Dystrophinopathies.

Bo Hoon Lee

    Continuum (Minneapolis, Minn.)
    |December 20, 2022
    PubMed
    Summary
    This summary is machine-generated.

    Dystrophinopathies are X-linked genetic disorders causing progressive weakness. Current management focuses on multidisciplinary care and corticosteroids, with emerging genetic therapies offering new hope for disease amelioration.

    More Related Videos

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
    09:39

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

    Published on: July 29, 2016

    15.5K
    Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
    10:30

    Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

    Published on: May 24, 2016

    18.8K

    Related Experiment Videos

    Last Updated: Aug 16, 2025

    CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
    07:44

    CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

    Published on: September 14, 2019

    8.5K
    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
    09:39

    Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

    Published on: July 29, 2016

    15.5K
    Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
    10:30

    Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

    Published on: May 24, 2016

    18.8K

    Area of Science:

    • Neuromuscular Disorders
    • Genetics
    • Therapeutics

    Background:

    • Dystrophinopathies encompass a range of X-linked genetic disorders.
    • Characterized by childhood-onset progressive muscle weakness, cardiac, and cognitive involvement.
    • Current mainstay therapy includes corticosteroids to slow disease progression.

    Approach:

    • Review of the history, epidemiology, genetics, and clinical presentation of dystrophinopathies.
    • Exploration of multidisciplinary management strategies.
    • Evaluation of established and emerging therapeutic interventions.

    Key Points:

    • Multidisciplinary care improves outcomes through early surveillance and management of respiratory, cardiac, and orthopedic health.
    • The advent of genetic therapeutics is transforming the treatment landscape for neuromuscular disorders.
    • Emerging strategies, including gene replacement therapy, aim for disease amelioration and dystrophin restoration.

    Conclusions:

    • The comprehensive management of dystrophinopathies is evolving with advancements in care and novel therapeutic approaches.
    • Genetic therapies represent a significant frontier in addressing the underlying causes and progression of these disorders.